Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection

AIDS

Volumn 16, Issue 13, 2002, Pages 1761-1765

  García, Felipe ^a   Plana, Montserrat ^a   Mestre, Gabriel ^a   Arnedo, Mireia ^a   Gil, Cristina ^a   Miró, José M ^a   Cruceta, Anna ^a   Pumarola, Tomas ^a   Gallart, Teresa ^a   Gatell, José M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Chronic HIV; Infection; Predictive factors; STI

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MITOGENIC AGENT; TETANUS TOXOID;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 18644384421     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209060-00008     Document Type: Article

References (13)

1. Martinez E, Mocroft A, García-Viejo M, et al. A prospective cohort study on the risk for lipodystrophy in HIV-1 infected patients treated with protease inhibitor-containing regimens. Lancet 2001, 357:592-598.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
3. Sereti I, Lane C. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. Clin Infect Dis 2001, 32:1738-1755.
4. Cohen D, Walker BD. Human immunodeficiency virus pathogenesis and prospects form immune control in patients with established infection. Clin Infect Dis 2001, 32:1756-1768.
5. Montaner L. Structured treatment interruptions to control HIV-1 and limit drug exposure. Trends Immunol 2001, 22:92-96.
6. Lori F, Lewis M, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000, 290:1591-1593.
7. Fagard C, Lebraz M, Gunthard H, et al. SSITT: A prospective trial of strategic treatment interruptions in 128 patients. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 357].
8. García F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001, 15:F29-F40.
9. Ruiz L, Carcelain G, Martinez-Picado J, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001, 15:F19-F27.
10. Plana M, García F, Gallart MT, et al. Immunological benefits of antiretroviral therapy in very early stages of asymtomatic chronic HIV-1 infection. AIDS 2000, 14:1921-1933.
11. Plana M, Garcia F, Gallart MT, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet 1998, 352:1194-1195.
12. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease [see comments]. Science 1997, 277:112-116.
13. Carcelain G, Tubiana R, Samri A, et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001, 75:234-241.